Open AccessA prospective study of the monitoring of patients with chronic myeloid leukemia upon withdrawal of tyrosine kinase inhibitor therapy
Author(s) -
А. Г. Туркина,
А. Л. Петрова,
Е Ю Челышева,
Oleg Shukhov,
Nikolay Tsyba,
А. К. Голенков,
Л. Л. Высоцкая,
А. В. Быкова,
Iriemchenko,
Galina A. Gusarova,
О. М. Поспелова,
Margarita Gurianova,
Irina Martynkevich,
А О Абдуллаев,
Andrey Sudarikov,
С. М. Куликов,
В Г Савченко
Publication year - 2020
Publication title -
gematologiâ i transfuziologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.126
H-Index - 5
eISSN - 2411-3042
pISSN - 0234-5730
DOI - 10.35754/0234-5730-2020-65-4-370-385
Subject(s) - medicine , imatinib , adverse effect , myeloid leukemia , tyrosine kinase inhibitor , prospective cohort study , imatinib mesylate , oncology , cancer
. The advent of tyrosine kinase inhibitors (TKIs) in clinical practice drastically improved prognosis in patients with chronic myeloid leukaemia (CML). Adverse events of the TKI therapy and its high nancial burden warrant the trend to gradually abandon this treatment. Aim . To assess the results of CML patient monitoring after the withdrawal of TKI therapy. Patients and methods . This prospective study included 98 chronic phase CML patients satisfying the criteria: any receiving of TKI therapy for ≥3 years; deep molecular response (DMR, BCR-ABL ≤ 0.01 % IS) during ≥ 2 years. The withdrawal was followed by quantitative BCR-ABL estimation performed monthly for the rst 6 months of the survey, bimonthly for 1 year and every 3 months from the second year onwards. Therapy was resumed at a loss of major molecular response (MMR, BCR-ABL ≥ 0.1 % IS). Results . The MMR loss upon the TKI withdrawal was observed in 48 (49 %) patients. Survival without MMR loss was 52 % past 24 months since withdrawal, with a median of 35 months (23–52). The duration of therapy, MR and the MR depth at the time of withdrawal signicantly correlated with a conserved post-therapy MMR. Gender, age, a Sokal risk group, type and line of TKI therapy at withdrawal, and imatinib resistance in history were not observed to signicantly impact molecular relapse-free remission. MMR was recovered in all 48 patients with TKI therapy resumed in molecular relapse. In 65 % of the patients, adverse therapy events observed during treatment completely resolved by 6 months of post-therapy monitoring. Musculoskeletal pain (withdrawal syndrome, WS) was reported in 42 % patients in the post-therapeutic period, which did not lead to TKI resumption. The WS development correlated with an elder age and longer therapy prior to withdrawal. Conclusion . Molecular relapse-free survival in CML patients with treatment-free remission (TFR) is comparable to other published evidence. Monitoring safety during TFR is attested by the lack of disease progression and MMR recovery upon TKI resumption in all patients.